Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: Systematic review and meta-analysis of observational studies

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 3, 2013, Pages 245-255

  Baandrup, Louise ^a   Faber, Mette T ^a   Christensen, Jane ^a   Jensen, Allan ^a   Andersen, Klaus K ^a   Friis, Søren ^a,b   Kjær, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Analgesics; gyne oncology; inflammation; meta analysis; ovarian neoplasms; review

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; DISEASE ASSOCIATION; ENDOMETRIOSIS; FAMILY HISTORY; HUMAN; IN VITRO STUDY; MEDLINE; OBSERVATIONAL STUDY; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CONFIDENCE INTERVALS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84874431031     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12069     Document Type: Review

References (55)

1. Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK,. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countries. Acta Obstet Gynecol Scand. 2005; 84: 1006-12.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
3. GLOBOCAN. Available from: http://globocan.iarc.fr (accessed 27 January 2012).
4. Hannibal CG, Cortes R, Engholm G, Kjaer SK,. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand. 2008; 87: 1353-60.
5. Ulrich CM, Bigler J, Potter JD,. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006; 6: 130-40.
6. Hussain SP, Harris CC,. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121: 2373-80.
7. Mills GB,. Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res. 2002; 8: 7-10.
8. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G,. Aspirin, salicylates, and cancer. Lancet. 2009; 373: 1301-9.
9. Algra AM, Rothwell PM,. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13: 518-27.
10. Ness RB, Cottreau C,. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999; 91: 1459-67.
11. Shan W, Liu J,. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009; 8: 3107-11.
12. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000; 11: 111-17.
13. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010; 126: 382-94.
14. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002; 8: 202-9.
15. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R,. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003; 3: 28.
16. Bonovas S, Filioussi K, Sitaras NM,. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol. 2005; 60: 194-203.
17. Bosetti C, Gallus S, La VC,. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006; 17: 871-88.
18. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10: 501-7.
19. Ni X, Ma J, Zhao Y, Wang Y, Wang S,. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol. 2012; 75: 26-35.
20. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012; 23: 1839-52.
21. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9: 933-7.
22. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC,. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer. 2009; 124: 1409-15.
23. Meier CR, Schmitz S, Jick H,. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 2002; 22: 303-9.
24. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE,. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009; 169: 1378-87.
25. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C,. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999; 28: 1-9.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. Br Med J. 2003; 327: 557-60.
27. Egger M, Davey SG, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997; 315: 629-34.
28. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S,. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol. 2000; 11: 1171-3.
29. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE,. Aspirin and epithelial ovarian cancer. Prev Med. 2001; 33: 682-7.
30. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H,. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2001; 10: 903-6.
31. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A,. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006; 17: 104-7.
32. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL,. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 2008; 167: 1430-7.
33. Merritt MA, Green AC, Nagle CM, Webb PM,. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008; 122: 170-6.
34. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM,. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer. 2008; 98: 1781-3.
35. Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010; 21: 1731-41.
36. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB,. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012; 23: 311-9.
37. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH,. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003; 88: 684-8.
38. Sørensen HT, Friis S, Nørgard B, Mellemkjær L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003; 88: 1687-92.
39. Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C,. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004; 108: 281-6.
40. Prizment AE, Folsom AR, Anderson KE,. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010; 19: 435-42.
41. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER,. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998; 351: 104-7.
42. Ammundsen HB, Faber MT, Jensen A, Høgdall E, Blaakær J, Høgdall C, et al. Use of analgesic drugs and risk of ovarian cancer-Results from a Danish case-control study. Acta Obstet Gynecol Scand. 2012; 91: 1094-1102.
43. Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1441-9.
44. Rodriguez C, Henley SJ, Calle EE, Thun MJ,. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet. 1998; 352: 1354-5.
45. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D,. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer. 1993; 55: 408-10.
46. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ,. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J. 2000; 320: 1642-6.
47. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr,. Aspirin use and risk of fatal cancer. Cancer Res. 1993; 53: 1322-7.
48. Friedman GD, Ury HK,. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980; 65: 723-33.
49. Pinheiro SP, Gates MA, Devivo I, Rosner BA, Tworoger SS, Titus-Ernstoff L, et al. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet. 2010; 1: 320-31.
50. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE,. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control. 2002; 13: 535-42.
51. Rosenberg L,. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med. 1995; 24: 107-9.
52. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379: 1602-12.
53. Horwitz RI, Feinstein AR,. The problem of "protopathic bias" in case-control studies. Am J Med. 1980; 68: 255-8.
54. Csizmadl I, Collet J-P, Boivin J,. Bias and confounding in pharmacoepidemiology. In:, Strom BL, (ed.). Pharmacoepidemiology, 4th edn. Bognor Regis: Wiley and Sons, 2007. pp. 791-810.
55. Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, et al. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer. 2006; 16 (Suppl 1): 247-53.